Evolve Private Wealth LLC Trims Holdings in Medpace Holdings, Inc. $MEDP

Evolve Private Wealth LLC lessened its holdings in Medpace Holdings, Inc. (NASDAQ:MEDP) by 28.7% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 2,655 shares of the company’s stock after selling 1,070 shares during the quarter. Evolve Private Wealth LLC’s holdings in Medpace were worth $1,275,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Balboa Wealth Partners boosted its stake in Medpace by 37.5% in the 1st quarter. Balboa Wealth Partners now owns 825 shares of the company’s stock worth $396,000 after purchasing an additional 225 shares in the last quarter. BI Asset Management Fondsmaeglerselskab A S increased its stake in Medpace by 247.1% during the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 51,598 shares of the company’s stock valued at $24,777,000 after purchasing an additional 36,731 shares in the last quarter. Hsbc Holdings PLC purchased a new position in Medpace in the fourth quarter worth about $2,164,000. Corient Private Wealth LLC raised its holdings in Medpace by 7.0% in the fourth quarter. Corient Private Wealth LLC now owns 1,830 shares of the company’s stock worth $1,029,000 after buying an additional 120 shares during the last quarter. Finally, Worthington Financial Partners LLC purchased a new position in Medpace in the 4th quarter worth approximately $1,082,000. 77.98% of the stock is currently owned by institutional investors.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $450.00, for a total transaction of $7,357,050.00. Following the transaction, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 20.50% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Robert W. Baird decreased their target price on Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. Wall Street Zen cut Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Royal Bank Of Canada lowered their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a report on Friday, April 24th. Weiss Ratings downgraded Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Monday, April 6th. Finally, BMO Capital Markets lowered their target price on shares of Medpace from $460.00 to $400.00 and set a “market perform” rating on the stock in a report on Friday, April 24th. Four analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $467.08.

Medpace Price Performance

Shares of MEDP stock opened at $473.48 on Wednesday. The company has a market cap of $13.52 billion, a PE ratio of 29.76, a price-to-earnings-growth ratio of 2.31 and a beta of 1.18. Medpace Holdings, Inc. has a 1 year low of $305.69 and a 1 year high of $628.92. The stock’s 50 day simple moving average is $450.81 and its two-hundred day simple moving average is $497.24.

Medpace (NASDAQ:MEDP) last announced its earnings results on Wednesday, April 22nd. The company reported $4.28 EPS for the quarter, topping analysts’ consensus estimates of $3.74 by $0.54. Medpace had a return on equity of 120.89% and a net margin of 17.19%.The firm had revenue of $706.60 million during the quarter, compared to analysts’ expectations of $697.82 million. During the same quarter in the previous year, the business earned $3.67 EPS. The company’s quarterly revenue was up 26.5% on a year-over-year basis. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities research analysts expect that Medpace Holdings, Inc. will post 17.04 EPS for the current year.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.